The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

February 3, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Etanercept Biosimilar Can Be Sold in Europe
On Jan. 16, 2016, the etanercept biosimilar referencing Enbrel was granted marketing authorization in the European Union (EU) to treat adults with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis.1 This effort is a collaboration between Biogen, Samsung, BioLogics and Samsung Bioepis. The product, called Benepali, should soon be available for patient use. Benepali is the first subcutaneous, anti-tumor necrosis factor-alpha (anti-TNF-α) biosimilar available in Europe.

You Might Also Like
  • Brodalumab Approved for Plaque Psoriasis
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
Also By This Author
  • Tildrakizumab Promising for Psoriasis in Patients with PsA

The approval was based on data from controlled, head-to-head Phase 1 and Phase 3 clinical trials, which compared Benepali with its reference, Enbrel. The 52-week, double-blind Phase 3 study randomized 596 patients with moderate to severe RA—despite methotrexate therapy—in 10 countries at more than 70 different sites. The primary endpoint was an ACR20 response at Week 24, whereby, Benepali had equivalent efficacy to Enbrel. The result was a 78% response for Benepali compared with an 80% response for Enbrel. At Week 52, comparable efficacy was sustained. Safety profiles of the biosimilar and reference product were comparable.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

FDA Is Reviewing Brodalumab
Brodalumab, an interleukin-17 (IL-17) receptor inhibitor, has been submitted to the FDA for possible approval to treat patients with moderate to severe plaque psoriasis. The agent works by hindering IL-17 activation at the receptor, thus preventing signal transmission that leads to inflammation.2 The Biologics License Application was submitted by AstraZeneca, in collaboration with Valeant Pharmaceuticals International, for a 210 mg brodalumab injection. The Prescription Drug User Fee Act action date assigned by the FDA is Nov. 16, 2016.

Submission data included three AMAGINE 3 clinical trials. At Week 12, patients who received 210 mg brodalumab had effective total psoriasis skin clearance compared with placebo and superior total psoriasis skin clearance compared with ustekinumab. More than 3,500 patients were enrolled in these trials. Adverse reactions included arthralgia, diarrhea, fatigue, headache and oropharyngeal pain.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should be evaluated for tuberculosis infection prior to initiating treatment.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Biogen. News Release: Benepali, the first etanercept biosimilar referencing Enbrel, approved in the European Union. 2016 Jan 16.
  2. Valeant Pharmaceuticals International Inc. News release: Valeant announces FDA acceptance of BLA submission for brodalumab in moderate to severe plaque psoriasis. 2016 Jan 25.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, brodalumab, etanercept, European Union, FDA, Food and Drug Administration

You Might Also Like:
  • Brodalumab Approved for Plaque Psoriasis
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • U.S. FDA Approves Biosimilar to Etanercept

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)